Comparative Pharmacology
Head-to-head clinical analysis: RAYOS versus STATROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAYOS versus STATROL.
RAYOS vs STATROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic glucocorticoid with anti-inflammatory, immunosuppressive, and metabolic effects; binds to glucocorticoid receptor, modulating gene expression and inhibiting phospholipase A2, cytokine production, and immune cell activity.
Statrol is a combination antibiotic ointment containing polymyxin B sulfate, neomycin sulfate, and gramicidin. Polymyxin B binds to lipopolysaccharides in the outer membrane of gram-negative bacteria, disrupting membrane integrity. Neomycin inhibits protein synthesis by binding to the 30S ribosomal subunit. Gramicidin alters cell membrane permeability in gram-positive bacteria by forming ion channels.
Initial adult dose 5-60 mg orally once daily, adjusted based on disease severity and response. Typically administered as a single dose in the morning with food.
10 mg orally once daily
None Documented
None Documented
2-3 hours (terminal); prolonged in hepatic impairment; circadian-timed formulation intended for once-daily morning dosing.
Terminal half-life 12-16 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: ~80% as inactive metabolites; fecal: ~5%; biliary: small amount.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites, 10% unchanged.
Category C
Category C
Corticosteroid
Otic Antibiotic/Corticosteroid